Emcure Pharmaceuticals has acquired the remaining 12.05% stake in Gennova Biopharmaceuticals for ₹23.18 crore to gain full ownership. Simultaneously, the company sold its mRNA business to Immunoscript Life Science for ₹139 crore. This move allows Emcure to sharpen its focus on the high-potential biologics and biosimilars market.
Emcure Pharmaceuticals Limited has moved to simplify its corporate structure by acquiring the entire 12.05% minority stake in its subsidiary, Gennova Biopharmaceuticals. This transaction, valued at ₹23.18 crore, consolidates Emcure’s control, making Gennova a wholly-owned subsidiary. The stake was previously held by former Gennova CEO Dr. Sanjay Singh and other investors.
Strategic Divestment and New Focus
Alongside the acquisition, Emcure has transferred Gennova’s mRNA business to Immunoscript Life Science Private Limited for ₹139 crore. Immunoscript is promoted by Dr. Sanjay Singh, who led the development of India's first mRNA COVID-19 vaccine. By divesting the mRNA vertical, Emcure is realigning Gennova to focus exclusively on its established biologics and biosimilars franchise. This segment includes key products such as Elaxim, Vintor, and Xgrast.
Under the new leadership of Samit Mehta, who has been appointed as Whole Time Director and CEO of Gennova, the company plans to leverage its existing biomanufacturing infrastructure. The strategy involves concentrating resources on biologics development and therapeutic platforms that align with the broader research and development goals of the parent group. Emcure’s management indicated that this shift is intended to improve operational focus and execution efficiency in the competitive biosimilars market.
Financial and Operational Impact
For investors, the financial impact of these transactions appears limited. Emcure reported that the mRNA unit contributed approximately ₹6.47 crore to its revenue, representing just 0.71% of the company's consolidated revenue of ₹911.58 crore. Consequently, the company stated that these moves are unlikely to cause a material change in its consolidated financials, debt reduction plans, or capital spending strategy.
This reorganization marks a generational shift in leadership at Gennova, moving toward a structure overseen by Samit Mehta, the son of Emcure founder Satish Mehta. As the company pivots toward biosimilars, investors may track future updates regarding the pipeline of these products, the progress of the biologics franchise, and any changes in operational margins as the firm streamlines its business model. The primary monitorable for shareholders will be how effectively the company can scale its biologics portfolio to drive revenue growth in the absence of the mRNA unit.